Study S000248

Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05073692
Acronym: ON TARGET DM
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 241981
Start: 2021-07-01
Primary completion: 2024-12-31
Lead sponsor: Kaiser Permanente
Conditions: Type 2 Diabetes Mellitus; Cardiovascular Diseases
Interventions: DRUG:SU; DRUG:DPP4; DRUG:SGLT2i; DRUG:GLP-1RA; DRUG:SGLT2i or GLP-1RA; DRUG:Linagliptin (DPP4); DRUG:Exenatide (GLP-1RA); DRUG:Liraglutide (GLP-1RA); DRUG:Empagliflozin (SGLT2i); DRUG:Glimepiride (SU); DRUG:Glipizide (SU); DRUG:Glimepiride (SU) or Glipizide (SU); DRUG:SU or DPP4 (excluding saxagliptin and alogliptin); DRUG:Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of 3-point Major Adverse Cardiovascular Events (MACE) [2.5 years]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0004097	Glucose-Lowering Medication Classes and Cardiovascular Outcomes in Patients With Type 2 Diabetes. Neugebauer R, JAMA network open	2025	Randomized trial	PMID 41091469 DOI	registry reference RESULT:41091469
R0005162	Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Rodriguez LA, Lancet regional health. Americas	2024	Nonrandomized study	PMID 38745886 DOI	registry reference RESULT:38745886